Related references
Note: Only part of the references are listed.Therapeutic and Prognostic Significance of Arachidonic Acid in Heart Failure
Ke Ma et al.
CIRCULATION RESEARCH (2022)
Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines
Hiroyuki Tsutsui
PHARMACOLOGY & THERAPEUTICS (2022)
Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products
Cheng-Peng Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Structure-Based Virtual Screening for Ligands of G Protein-Coupled Receptors: What Can Molecular Docking Do for You?
Flavio Ballante et al.
PHARMACOLOGICAL REVIEWS (2021)
Single-cell reconstruction of the adult human heart during heart failure and recovery reveals the cellular landscape underlying cardiac function
Li Wang et al.
NATURE CELL BIOLOGY (2020)
Single-Cell Reconstruction of Progression Trajectory Reveals Intervention Principles in Pathological Cardiac Hypertrophy
Zongna Ren et al.
CIRCULATION (2020)
Innate Immune Nod1/RIP2 Signaling Is Essential for Cardiac Hypertrophy but Requires Mitochondrial Antiviral Signaling Protein for Signal Transductions and Energy Balance
Han-Bin Lin et al.
CIRCULATION (2020)
Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals
Toshiaki Ohkuma et al.
DIABETOLOGIA (2019)
JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework
Aziz Khan et al.
NUCLEIC ACIDS RESEARCH (2018)
Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia
Matthew L. Edin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics
John D. Imig
PHARMACOLOGY & THERAPEUTICS (2018)
CYP2J2 and its metabolites (epoxyeicosatrienoic acids) attenuate cardiac hypertrophy by activating AMPK2 and enhancing nuclear translocation of Akt1
Bei Wang et al.
AGING CELL (2016)
Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials
Ewa A. Jankowska et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Epoxyeicosatrienoic Acid as Therapy for Diabetic and Ischemic Cardiomyopathy
Mikhail Romashko et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II
Zuowen He et al.
CARDIOVASCULAR RESEARCH (2015)
miR-217 Mediates the Protective Effects of the Dopamine D2 Receptor on Fibrosis in Human Renal Proximal Tubule Cells
Fei Han et al.
HYPERTENSION (2015)
Systematic Metabolomic Analysis of Eicosanoids after Omega-3 Polyunsaturated Fatty Acid Supplementation by a Highly Specific Liquid Chromatography-Tandem Mass Spectrometry-Based Method
Xu Zhang et al.
JOURNAL OF PROTEOME RESEARCH (2015)
NIH to balance sex in cell and animal studies
Janine A. Clayton et al.
NATURE (2014)
Anti-inflammatory Effects of ω-3 Polyunsaturated Fatty Acids and Soluble Epoxide Hydrolase Inhibitors in Angiotensin-II-Dependent Hypertension
Arzu Ulu et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2013)
Cytochrome P450 2J2 is protective against global cerebral ischemia in transgenic mice
Rui Li et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2012)
EET agonist prevents adiposity and vascular dysfunction in rats fed a high fat diet via a decrease in Bach 1 and an increase in HO-1 levels
Komal Sodhi et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2012)
Soluble Epoxide Hydrolase Inhibitors and Heart Failure
Hong Qiu et al.
CARDIOVASCULAR THERAPEUTICS (2011)
Epidemiology and risk profile of heart failure
Anh L. Bui et al.
NATURE REVIEWS CARDIOLOGY (2011)
Pharmacological inhibition of the soluble epoxide hydrolase - from mouse to man
Marc Revermann
CURRENT OPINION IN PHARMACOLOGY (2010)
Effects of Heart Rate and Anesthetic Timing on High-Resolution Echocardiographic Assessment Under Isoflurane Anesthesia in Mice
Jian Wu et al.
JOURNAL OF ULTRASOUND IN MEDICINE (2010)
Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches
Ning Li et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2009)
Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo
Atsuko Motoki et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
Kenneth Dickstein et al.
EUROPEAN JOURNAL OF HEART FAILURE (2008)
Eicosanoids and renal damage in cardiometabolic syndrome
John D. Imig
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Tackling heart failure in the twenty-first century
James O. Mudd et al.
NATURE (2008)
Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease
Jan Monti et al.
NATURE GENETICS (2008)
Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo
Ding Ai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors
Danyan Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility
IH Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids
M Spiecker et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2005)
Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation
CJ Sinal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
